Merck & Co., Inc. MRK shares are now nearly unchanged at $54.92 in Wednesday's session.
In just days (October 26 and 27), the stock fell from $61.99 to $54.71.
The first leg of the decline came after the its mixed Q3 report and raised guidance. The second leg lower was instigated by a Morgan Stanley downgrade. On the second day of the swoon, the stock bottomed at $54.41 and that provided the foundation for a rebound that peaked on November 8 at $56.72.
After a lower open today, Merck tested the validity of that low when it reached $54.40 and rallied to $55.19. It's attempting to remain in the $55.00 handle.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.